193014-01-6

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 3-amino-2-nitro-, ethyl ester (9CI) is used as an intermediate in the synthesis of various pharmaceuticals due to its ability to participate in a range of chemical reactions, facilitating the creation of diverse medicinal compounds.
Used in Dye Industry:
In the dye industry, Benzoic acid, 3-amino-2-nitro-, ethyl ester (9CI) is utilized as a precursor for the production of dyes, leveraging its chemical structure to contribute to the color and properties of the final dye products.
Used in Fragrance Industry:
Benzoic acid, 3-amino-2-nitro-, ethyl ester (9CI) is employed as a building block in the fragrance industry, where its chemical properties are harnessed to create a variety of scent compounds used in perfumes and other aromatic products.
Used in Organic Chemistry Research:
Due to its unique structure and reactivity, Benzoic acid, 3-amino-2-nitro-, ethyl ester (9CI) is used in organic chemistry research for studying reaction mechanisms and developing new synthetic pathways for organic compounds.

Upstream product

• 54002-28-7 3-acetylamino-2-nitro-benzoic acid 
• 64-17-5 ethanol 

Downstream Products

• 1255927-15-1 ethyl 2-nitro-3-(1H-pyrrol-1-yl)benzoate 
• 1255926-93-2 C₁₉H₁₄N₆ 
• 1255927-16-2 ethyl 2-amino-3-(1H-pyrrol-1-yl)benzoate 
• 1255927-31-1 ethyl 1-[3-(ethoxycarbonyl)-2-nitrophenyl]-1H-imidazole-5-carboxylate 
• 1255927-25-3 N-(2-fluorophenyl)-6-(4H-1,2,4-triazol-2-yl)pyrrolo[1,2-a]quinoxalin-4-amine 
• 1255926-92-1 C₁₉H₁₃ClN₆ 
• 193014-02-7 3-acetylamino-2-nitro-benzoic acid ethyl ester 

Relevant academic research and scientific papers

Benzimidazole compounds

A benzimidazole compound represented by the formula (I): wherein R3is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.

Benzimidazole derivatives

PCT No. PCT/JP96/03858 Sec. 371 Date Nov. 2, 1998 Sec. 102(e) Date Nov. 2, 1998 PCT Filed Dec. 27, 1996 PCT Pub. No. WO97/24334 PCT Pub. Date Jul. 10, 1997Novel benzimidazole derivatives represented by the formula (I): wherein R3 is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.